Rayca Precision partners with ASAKE on AI-designed therapeutics

▤ Summary

Rayca Precision has partnered with ASAKE to combine AI drug discovery with translational biotech capabilities for rare and metabolic disease programs. The collaboration links Rayca’s physics-aware AI engine with ASAKE’s strengths in biosynthetic technology, synthetic chemistry, and emerging modalities. The companies have already generated early laboratory data and are now repeating and independently confirming the results. They plan to move programs through preclinical milestones, developability screening, and IND-enabling readiness for future out-licensing or biopharma partnering.

▦ Linked Companies

Rayca Precision

$1M to $5M